We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Show more
Ask ADVFN Intelligence (AI)
FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...
AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.6754 | 185.208932125 | 0.9046 | 2.6592 | 0.81 | 3712659 | 1.85844044 | CS |
| 4 | 1.9266 | 294.857667585 | 0.6534 | 2.6592 | 0.5895 | 997220 | 1.78597693 | CS |
| 12 | 1.964 | 318.831168831 | 0.616 | 2.6592 | 0.45 | 362506 | 1.56607494 | CS |
| 26 | 1.47 | 132.432432432 | 1.11 | 2.6592 | 0.45 | 226610 | 1.34943604 | CS |
| 52 | -3.42 | -57 | 6 | 6 | 0.45 | 133111 | 1.43691769 | CS |
| 156 | -3.42 | -57 | 6 | 6 | 0.45 | 133111 | 1.43691769 | CS |
| 260 | -3.42 | -57 | 6 | 6 | 0.45 | 133111 | 1.43691769 | CS |
| Symbol | Price | Vol. |
|---|---|---|
| EONREON Resources Inc | US$ 1.33 (30.39%) | 133.45M |
| MSTUT Rex 2X Long MSTR Daily Target ETF | US$ 12.685 (-3.39%) | 66.6M |
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 33.69 (3.69%) | 60.46M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5.79 (-2.53%) | 52.66M |
| TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 2.13 (1.43%) | 48.58M |
Invest-in-America
10 hours ago
tw0122
11 hours ago
Invest-in-America
11 hours ago
Invest-in-America
12 hours ago
glenn1919
4 days ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
